fbpx

Weekly Top News – IBD – August 26, 2019

August 26, 2019

etrasimod (APD334) / Arena
Etrasimod clinical trial estimate: Data from P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in H2 2021 (Wells Fargo) – Aug 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67741783; Page no: 2; REPORT TITLE: “Update from San Francisco biotech access day”; AUTHOR: Research Department; DATE: 08/02/2019

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RHB-104 clinical trial estimate: Initiation of P3 trial for Crohn’s disease in Q1 2020(Ladenburg, Thalmann) – Aug 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67673924; Page no: 1; REPORT TITLE: “Redhill Biopharma Ltd 2Q19 results; Talica PDUFA November 2, 2019; Buy and $24 PT”; AUTHOR: Kaplan, Matthew, et al; DATE: 07/24/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
NICE’s fast-track catapults Skyrizi into market (PMLive) – Aug 21, 2019 – “NICE has published a final recommendation for AbbVie and Boehringer Ingelheim’s Skyrizi today, completing a fast-track process which will see the new psoriasis treatment gain market access in record time….Accelerates the review process and also cuts the standard 90 day implementation period down to 30 days. This means the NHS across England has a month from today to make preparations for prescribing of Skyrizi to begin….SVB Leerink analyst Geoffrey Porges predicts $3bn in peak sales for AbbVie’s Skyrizi, with its success dependent on how it will fare not just in psoriasis but the other hotly-contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.”

 

Otezla (apremilast) / Celgene
Bristol-Myers Squibb announces agreement between Celgene and Amgen to divest Otezla for $13.4 billion (Businesswire) – Aug 26, 2019 – “Bristol-Myers Squibb Company…announced today that Celgene Corporation…has entered into an agreement with Amgen…under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash….The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC)…’establishing OTEZLA as an important medicine for patients with psoriasis, psoriatic arthritis and Behçet’s Disease’…Bristol-Myers Squibb now expects the pending merger with Celgene to close by the end of 2019.”

 

Humira (adalimumab) / Eisai, AbbVie
Humira pricing: Wholesale acquisition cost of $57,000/year (UBS) – Aug 24, 2019 – A subscription to Thomson ONE is required to gain full access to report 67836265; Page no: 1; REPORT TITLE: “AbbVie Inc- First read: AbbVie “Upadacitinib approval mostly in-line w/ expectations””; AUTHOR: Jacob, Navin, et al; DATE: 08/16/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent expiry: 2022 (NH Inv.) – Aug 22, 2019 – A subscription to Thomson ONE is required to gain full access to report 67851543; Page no: 21; REPORT TITLE: “Medy Tox Inc – Initiating coverage – Medytox-Ready to cross the great wall-08/21/2019”; AUTHOR: Ra, Ryan, et al; DATE: 08/21/2019

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RHB-104 patent expiry: 2019-2038 (Ladenburg, Thalmann) – Aug 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67570515; Page no: 8; REPORT TITLE: “Redhill Biopharma Ltd Priority review for Talicia (RHB-105); PDUFA November 2, 2019; Buy and $24 PT”; AUTHOR: Kaplan, Matthew, et al; DATE: 07/03/2019

 

etrasimod (APD334) / Arena
Etrasimod share value projection: $56/share to Arena Pharmaceutical (RBC Capital Markets (Canada)) – Aug 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67780220; Page no: 2; REPORT TITLE: “Arena Pharmaceuticals, Inc. – Q2:19 post-call: ARNA clinical execution continues with trials fully funded”; AUTHOR: Mackay, Kenen, et al; DATE: 08/07/2019

 

PTG-200 / Protagonist Therapeutics, J&J
PTG-200 share value projection: $4.50/share to Protagonist Therapeutics (H.C. Wainwright & Co) – Aug 21, 2019 – A subscription to Thomson ONE is required to gain full access to report 67785243; Page no: 2; REPORT TITLE: “Protagonist Therapeutics Inc – PTG-300 broadens its horizons; Reiterate Buy”; AUTHOR: Research Department; DATE: 08/08/2019

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RHB-104 share value projection: $9/share to RedHill (Roth Capital) – Aug 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67668922; Page no: 2; REPORT TITLE: “Redhill Biopharma Ltd RDHL: 2Q19 Recap – Focus on Talicia (PDUFA Nov 2)”; AUTHOR: Henry, Scott, et al; DATE: 07/23/2019

No Comments

Post a Comment

Comment
Name
Email
Website